New Type 2 Drugs Change Treatment Decisions

Metformin, the cornerstone in treating type 2 diabetes, saw an increase in usage among type 2s from 23 percent of that population in 1997 to 53 percent in 2012. But that increase has since plateaued due to the introduction of additional drugs that target insulin secretion and glucose regulation. DPP-4 inhibitors, such as Januvia and Onglyza, now account for 21 percent of treatments. Long-acting insulins,

Read more

Diabetes Patients on Insulin Sensitizers Run Lower PAD Risk

Insulin sensitizers–drugs that increase sensitivity to insulin such as Avandia and Actos–could help lessen the risk of peripheral arterial disease (PAD) for those with type 2 diabetes, according to a new study. That’s great news for the 8 million Americans who are currently battling PAD, a disease that causes narrowing of the arteries, leading to decreased blood flow to the legs. It leads to pain,

Read more

FDA Panelists Vote to Ease Up on Avandia

A significant majority-20 of 26 members attending a combined meeting of FDA advisory committees-has voted to modify or remove the current restrictive label and distribution regulations affecting the type 2 drug Avandia. Avandia (rosiglitazone), manufactured by GlaxoSmithKline, was introduced in 1999 The drug, a thiazolidinedione (TZD), works by increasing the sensitivity of cells to insulin. A beneficial side effect of the drug was that it

Read more

US Sale of Generic Actos Gets FDA Nod

The Food and Drug Administration has approved US sale of generic pioglitazone (trade name Actos) for the treatment of type 2 diabetes. Actos, originally developed and trademarked by Takeda Pharmaceuticals, works by decreasing insulin resistance in type 2 patients. The prescription drug, which belongs to the class of drugs known as thiazolidinediones (TZDs), has enjoyed great commercial success in the United States since its introduction

Read more